SCHEMBL3899480

SCHEMBL3899480

Cc1ccc(C(=O)N[C@H](C)c2ccc(F)cc2F)c(NS(=O)(=O)C2=CC=CN3SNC=C23)c1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR139 Q6DWJ6 2/20 0.34
KCNA5 P22460 1/20 0.33
NR1I2 O75469 1/20 0.32
SCN1A P35498 1/20 0.32
SCN1B Q07699 1/20 0.32
SCN5A Q14524 1/20 0.32
SCN8A Q9UQD0 1/20 0.32
PPARG P37231 1/20 0.32
MEN1 O00255 1/20 0.31
MAPT P10636 1/20 0.31
KMT2A Q03164 1/20 0.31
PDE2A O00408 2/20 0.31
SLC22A2 O15244 2/20 0.31
ACLY P53396 1/20 0.30
SLC10A2 Q12908 1/20 0.30
SLC10A1 Q14973 1/20 0.30
SLC10A6 Q3KNW5 1/20 0.30
PDPK1 O15530 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3907629 0.95 NR1I2 (0.33) GPR139NR1I2SCN1ASCN1BSCN5A
SCHEMBL3903821 0.91 NR1I2 (0.33) GPR139NR1I2SCN1ASCN1BSCN5A
SCHEMBL1890458 0.91 CCKBR (0.33) GPR139NR1I2SCN1ASCN1BSCN5A
SCHEMBL3900169 0.91 CCR2 (0.37) KCNA5NR1I2SCN1ASCN1BSCN5A
SCHEMBL5728253 0.91 NR1I2 (0.33) GPR139NR1I2SCN1ASCN1BSCN5A
SCHEMBL3902491 0.90 KCNA5 (0.38) KCNA5PPARGMEN1MAPTKMT2A
SCHEMBL3899485 0.90 PDE2A (0.40) GPR139PDE2AACLY
SCHEMBL3901585 0.88 KCNA5 (0.38) KCNA5NR1I2SCN1ASCN1BSCN5A
SCHEMBL3906717 0.87 L3MBTL1 (0.38) KCNA5PPARGMEN1MAPTKMT2A
SCHEMBL3896549 0.86 L3MBTL1 (0.38) KCNA5NR1I2SCN1ASCN1BSCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7241759-B2 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-10 US claimed
US-7550492-B2 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2009-06-23 US disclosed
US-20070276016-A1 BENZO[1,2,5]THIADIAZOLE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-29 US disclosed
US-7241759-B2 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-10 US disclosed
US-20040224983-A1 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276016-A1 BENZO[1,2,5]THIADIAZOLE COMPOUNDS CCKBR, CCKAR, GIPR GPR139 1564/4885KCNA5 4123/4885NR1I2 45/4885
US-20040224983-A1 Benzo[1,2,5]thiadiazole compounds CCKBR, CCKAR, BRSK2 GPR139 1493/4885KCNA5 3959/4885NR1I2 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.